Very early this morning, our first half a million doses of the AstraZeneca-Oxford vaccine from the Serum Institute arrived in Canada, said Prime Minister Justin Trudeau

Some 500,000 doses made by SII, the world's largest vaccine producer, are set to arrive in Canada on Wednesday, a surprise boost for Canada's lagging vaccination drive

\"The real motivation here is actually exfiltrating intellectual property and getting a competitive advantage over Indian pharmaceutical companies,\" says Cyfirma Chief Executive Kumar Ritesh

Providing a final clearance for the vaccine a day after it was authorized by U.S. regulators, the Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the vaccine from J&J as appropriate for Americans 18 and older

The Food and Drug Administration said Thursday that it's allowing the additional option after reviewing new data from New York-based Pfizer and its German partner, BioNTech

The real-world study involved around 1.2 million people in Israel. Pfizer vaccine has also proved to be effective against B.1.1.7 variant, also known as the UK variant of coronavirus

Located in the city of Pune in Maharashtra, the SII is the world's largest vaccine manufacturer by volume

AstraZeneca's statement late in the day said the company was striving to increase productivity to deliver the promised 180 million doses

Data analysed by Public Health England (PHE) showed the Pfizer provided high levels of protection against infection and symptomatic disease from a single dose

Up to 4 million Australians are expected to be inoculated by March, with Morrison among a small group receiving the first round of the Pfizer-BioNTech vaccine

Symptoms, as reported in clinical trials for the AstraZeneca shot, can include a high temperature or headache and are a normal sign that the body is generating an immune response

Phil Dormitzer, one of Pfizer's top viral vaccine scientists, said in an interview that he believes the current vaccine is highly likely to still protect against the concerning variant first discovered in South Africa

South African variant could significantly reduce vaccine protection, says Pfizer A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer-BioNTech vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday. Companies are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed. COV...

Pfizer and BioNTech said they were doing similar lab work to understand whether their vaccine is effective against another variant first found in Brazil

The vaccines currently approved for emergency use in India are Covishield, from the Oxford-AstraZeneca stable manufactured by Pune's Serum Institute of India, and Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology (NIV)

National Intelligence Service (NIS), the chief intelligence agency of South Korea informed lawmakers about the alleged cyber breach on Tuesday, February 16, during a closed-door briefing to a parliamentary intelligence committee

Serum Institute has applied for registration with Health Canada with the help of Toronto-based Verity Pharmaceuticals, Adar Poonawalla said

COVID-19 vaccine: The AstraZeneca-Oxford product is a viral vectored vaccine called ChAdOx1-S [recombinant], which is being produced at several manufacturing sites, as well as in the Republic of Korea and India

In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data

The research, published in the journal Nature Medicine, noted that the vaccine is effective against coronavirus variants carrying the N501Y and E484K mutations